Ingrid Choong
Net worth: 3 396 $ as of 29/04/2024
Career history of Ingrid Choong
Former positions of Ingrid Choong
Companies | Position | Start | End |
---|---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | 31/08/2023 |
Investor Relations Contact | 31/12/2007 | - | |
Public Communications Contact | 31/12/2007 | - | |
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Investor Relations Contact | - | 28/03/2016 |
Corporate Officer/Principal | 10/08/2011 | - | |
VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/1998 | 31/12/2007 |
Training of Ingrid Choong
California Institute of Technology | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistics
International
United States | 6 |
Operational
Investor Relations Contact | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Ingrid Choong
- Experience